Excerpts

14.0, p = 0.011), while there was a decreasing trend in diarrhea (15.9 vs. 20.4, p = 0.214). 3.3.2.

The RNA sequencing database from a GBM patient cohort (156 patients, four non-tumor controls) showed a trend toward upregulated expression of CCL21 ( p = 0.22, Supplemental Figure S1A ).

Analysis of the distribution of age at diagnosis (logS~age at diagnosis) of patients with REC-III variants showed a trend for a higher age at diagnosis for the subgroup with established IP variants (IP: median 15.2 (4.8–39.3) vs. no IP observed: median 8.5 (0.9–45.1), p = 0.23) ( Figure 5 ).

For OS, pure transformation showed only a nonsignificant trend toward worse survival compared with de novo DLBCL ( p = 0.23), and OS did not differ significantly among de novo DLBCL, concurrent trDLBCL, and pure transformation (log-rank p = 0.56; Figure S1 ).

Cyclophosphamide dose, which appeared nominally significant in the untransformed analysis ( Supplementary Table S1 ), was not replicated in the log-transformed model (β = −0.001, p = 0.235), suggesting that the original signal reflected the combined influence of AMH non-normality, regimen-structured collinearity, and the small number of cyclophosphamide-treated patients ( n = 12/75) rather than a true independent pharmacological effect.

Subgroup analysis showed significantly higher HR from retrospective studies (HR: 1.89, 95% CI: 1.09–3.29, z = 2.27, p = 0.02, τ 2 = 0.20, I2 = 44.71%), while such a significant trend was not confirmed pooling results from RCTs (HR: 1.70, 95% CI: 0.70–4.08, z = 1.18, p = 0.24, τ 2 = 0.61, I2 = 63.91%), among which a significant heterogeneity occurred ( Supplementary Materials—Figure S12 ).

Meanwhile, PSA and mSEPT9 differences remained insignificant, indicating a possible trend ( p = 0.240 and 0.263, respectively).

Lobectomy demonstrated borderline significance compared with segmentectomy (OR 1.30, p = 0.24). 3.4.

Intriguingly, patients of over 60 years showed a trend towards better GHS scores than the younger patients in follow-up care (74.14% vs. 64.72%, p = 0.241).

Regarding the subgroup of patients with a TPS score > 50%, the parameter PET-Skewness also showed a trend in favor of patients with a value below the above-mentioned threshold (HR for disease progression or death, 0.57; 95% CI, 0.22 to 1.48; p = 0.247; Figure 5 A).

In normal tissue samples from tumor proximity (n = 30), a high stromal CD66b+ cell density was a negative prognostic factor ( p = 0.037) ( Figure 2 C), while in normal tissue from the periphery of resected tissue, only a weak trend towards worse prognosis was observed ( p = 0.250) ( Figure 2 D).

The initial multivariate model included the following five factors that were found to be significant or marginally significant ( i.e ., p < 0.25) based on the initial screen: initial cytogenetic, previous disease/prior SCT, age at transplant, transplant type/source and conditioning intensity.

On the multivariate level using parameters from the univariate analysis with a statistical trend of p < 0.25, no significant risk factors could be detected.

Heterozygous patients showed a trend towards an increased risk of melanoma death (HR 1.46 [95% CI 0.76–2.83], p = 0.26).

In the colon cancer cohort, Kaplan–Meier curves revealed that MSI-H patients showed a trend toward favorable survival probability ( n = 348, p = 0.270; Figure 4 A), but this association was not observed for those in the rectal cancer cohort ( n = 373, p = 0.866; Figure 4 B).

A decreasing trend of repeat biopsies ( p = 0.910) and an increasing trend of PCa family history ( p = 0.296) regarding men with benign tissue, iPCa, and csPCa were observed.

The perfusion fraction showed a trend for correlation with the median k PL ( p = 0.30, r = −0.58; Figure 2 c).

The addition of anti-VEGF therapy showed a trend toward potential benefit compared with chemotherapy only (mPFS, 6.1 vs. 4.8 months, p = 0.3).

In the univariate model, Karnofsky performance status > 80% was associated with a significantly better PFS (HR 0.37, 95% CI 0.19–0.76, p = 0.003), and CCI ≤ 2 showed a nonsignificant trend toward improved outcomes (HR 0.73, 95% CI 0.40–1.34, p = 0.3).

OS did not significantly differ between patients treated with PCI-27483- GEM and those with GEM alone but there was a nonsignificant trend toward longer PFS in patients receiving PCI-27483- GEM compared to those receiving GEM alone (PFS: 3.7 months vs. 1.9 months; HR 0.62; p = 0.307) [ 99 ].

Affected ankle dorsiflexion strength least squared z-scores also showed a trend towards improvement over the follow-up period, without reaching statistical significance ( p = 0.34).

However, in patients receiving adjuvant treatment (radiotherapy or chemo-radiotherapy), although a decreasing trend was observed at 6 months, the decline was not statistically significant post-radiotherapy ( p = 0.414; adjusted p = 0.827) and chemo-radiotherapy ( p = 0.235; adjusted p = 0.235).

The study comparing the combination therapy of carboplatin and gemcitabine with gemcitabine monotherapy showed a trend toward longer overall survival (OS) (6.7 months vs. 4.8 months, p = 0.49) and progression free survival (PFS) (4.1 months vs. 3.0 months, p = 0.36) in the combination therapy group, although the results were not statistically significant [ 13 ].

Interestingly, patients in the en bloc resection group showed a trend to initiate radiotherapy more rapidly, thus without statistical significance (mean time to therapy: 28 days, vs. 40 days in the EI group), p = 0.49.

Radiotherapy exposure showed a nonsignificant trend toward increased risk (HR 1.79; 95% CI 0.29–11.19; p = 0.49).